Literature DB >> 7348568

Combined chemo-hormonal therapy in breast cancer: a hypothesis.

C K Osborne.   

Abstract

Results of treatment for advanced breast cancer have plateaued indicating the need for new treatment approaches. One such approach, combined endocrine therapy and cytotoxic chemotherapy, has had limited success in current clinical trials. This lack of synergism could be due to the effect of endocrine therapy on tumor cell kinetics, which could inhibit the activity of the cytotoxic drug. Proper sequencing of the two treatment modalities may increase the therapeutic ratio.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7348568     DOI： 10.1007/bf01805864

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  2 in total

1.  Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA.

Authors:  E M GREENSPAN; M FIEBER; G LESNICK; S EDELMAN
Journal:  J Mt Sinai Hosp N Y       Date:  1963 May-Jun

2.  The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer.

Authors:  S K Carter
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872
  2 in total
  6 in total

1.  Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.

Authors:  Davide Bedognetti; Mario Roberto Sertoli; Paolo Pronzato; Lucia Del Mastro; Marco Venturini; Paola Taveggia; Elisa Zanardi; Guido Siffredi; Simona Pastorino; Paola Queirolo; Giovanni Gardin; Ena Wang; Clara Monzeglio; Francesco Boccardo; Paolo Bruzzi
Journal:  J Natl Cancer Inst       Date:  2011-09-15       Impact factor: 13.506

Review 2.  Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three?

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman B Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne
Journal:  Lancet       Date:  2009-12-10       Impact factor: 79.321

4.  Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.

Authors:  C G Kardinal; M C Perry; V Weinberg; W Wood; S Ginsberg; R N Raju
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?

Authors:  R Mick; C B Begg; K H Antman; A H Korzun; E Frei
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

6.  Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells.

Authors:  M Bontenbal; A M Sieuwerts; J G Klijn; H A Peters; H L Krijnen; P Sonneveld; J A Foekens
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.